Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors.
Achieving hemostasis in patients with hemophilia A or B is complicated by the presence of inhibitors and is made even more difficult when these individuals require surgery. Over a 4-year period, 6 patients with inhibitors to factor VIII and 1 patient with inhibitors to factor IX underwent surgery or invasive procedures at our institution. A total of 26 procedures were performed, primarily using the bypassing agent FEIBA for bleeding control. Excellent hemostasis was obtained in all cases, adding to accumulating data indicating that FEIBA is safe and effective in hemophilia patients with inhibitors who require surgery.
Stine
Kimo C
KC
Department of Pediatrics, Hematology/Oncology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, AR 72202, USA. StineKimoC@uams.edu
Shrum
Dixie
D
Becton
David L
DL
D000293:Adolescent; D000328:Adult; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D001779:Blood Coagulation Factors / Q000008:administration & dosage*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002675:Child, Preschool; D006467:Hemophilia A / Q000097:blood / Q000601:surgery*; D002836:Hemophilia B / Q000097:blood / Q000601:surgery*; D006487:Hemostasis / Q000187:drug effects; D006488:Hemostasis, Surgical; D006801:Humans; D007223:Infant; D008297:Male
D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; C065655:anti-inhibitor coagulant complex